Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study
2017 · Clinical Cancer Research · 108 citations
https://doi.org/10.1158/1078-0432.ccr-17-2781
F
Ferdinando De Vita
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
346
Papers
10.1K
Citations
54
h-index
169
i10-index
Ferdinando De Vita is an academic researcher from University of Campania "Luigi Vanvitelli". The author has contributed to research in topics: Gastric Cancer Management and Outcomes & Colorectal Cancer Treatments and Studies & HER2/EGFR in Cancer Research. The author has an h-index of 54, co-authored 295 publications.
ORCID: 0000-0002-7654-7470Papers by this author
worksPhase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer
2006 · British Journal of Cancer · 82 citations
https://doi.org/10.1038/sj.bjc.6603141
Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target
2010 · Cancer Treatment Reviews · 80 citations
https://doi.org/10.1016/s0305-7372(10)70014-1
Neutrophil to lymphocyte ratio (NLR) for prediction of distant metastasis-free survival (DMFS) in early breast cancer: a propensity score-matched analysis
2016 · ESMO Open · 79 citations
https://doi.org/10.1136/esmoopen-2016-000038
A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer
2011 · British Journal of Cancer · 45 citations
https://doi.org/10.1038/sj.bjc.6606093
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort
2021 · ESMO Open · 30 citations
https://doi.org/10.1016/j.esmoop.2020.100032
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat